Thrombolytic therapy in acute pulmonary embolism

Current Opinion in Cardiology

Volumn 27, Issue 6, 2012, Pages 585-591

  Tapson, Victor F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

catheter based thrombolysis; pulmonary embolism; submassive pulmonary embolism; thrombolytic therapy

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; FIBRINOLYTIC AGENT; STREPTOKINASE; TENECTEPLASE; TISSUE PLASMINOGEN ACTIVATOR; TROPONIN I; TROPONIN T; UROKINASE;

ACUTE DISEASE; ACUTE PULMONARY EMBOLISM; BLEEDING TENDENCY; BRAIN HEMORRHAGE; BRAIN INJURY; BRAIN SURGERY; BRAIN TUMOR; CARDIOVASCULAR MORTALITY; CATHETER COMPLICATION; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DISEASE PREDISPOSITION; DRUG CONTRAINDICATION; ELECTROCARDIOGRAM; EMBOLECTOMY; EVIDENCE BASED MEDICINE; FIBRINOLYTIC THERAPY; HEART RIGHT VENTRICLE FAILURE; HUMAN; HYPERTENSION; LOADING DRUG DOSE; LUNG EMBOLISM; MEDICAL HISTORY; META ANALYSIS (TOPIC); PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; T WAVE INVERSION; TREATMENT DURATION;

ACUTE DISEASE; ALGORITHMS; CATHETERIZATION; EMBOLECTOMY; FIBRINOLYTIC AGENTS; HUMANS; PULMONARY EMBOLISM; RISK ASSESSMENT; THROMBOLYTIC THERAPY;

EID: 84868297683     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0b013e328358308c     Document Type: Review

References (32)

1. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986; 315:1109-1114.
2. Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet 1960; 1:1309-1312.
3. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecularweight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119 (1 Suppl):64SY94S. 4. Cruickshank MK, Levine MN, Hirsh J, et al. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 1991; 151:333-337.
4. Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a 'standard care' nomogram. A randomized controlled trial. Ann Intern Med 1993; 119:874-881.
5. Tapson VF, Hyers TM, Waldo AL, et al. Antithrombotic therapy practices in US hospitals in an era of practice guidelines. Arch Intern Med 2005; 165:1458-1464.
6. Cohen AT, Tapson VF, Bergmann JF, et al. A large-scale, global observational study of venous thromboembolism risk and prophylaxis in the acute hospital care setting. The ENDORSE study. Lancet 2008; 371:387-394.
7. Tapson VF. Acute pulmonary embolism. N Engl J Med 2008; 358:1037-1052.
8. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141 (2 Suppl):e419SYe494S. The ACCP continues to publish an evidence-based set of guidelines on treatment of acute VTE. Unfortunately, for our topic of thrombolytic therapy in acute pulmonary embolism, the evidence base is limited and the guidelines in this area are not very helpful to the practicing clinician faced with acute pulmonary embolism. 10. Konstantinides S, Geibel A, Heusel G, et al. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002; 347:1143-1150.
9. Goldhaber SZ, Haire WD, Feldstein ML, et al. Alteplase versus heparin in acute pulmonary embolism: Randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet 1993; 341:507-511.
10. Ribeiro A, Lindmarker P, Juhlin-Dannfelt A, et al. Echocardiography Doppler in pulmonary embolism: Right ventricular dysfunction as a predictor of mortality rate. Am Heart J 1997; 134:479-487.
11. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: Clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353:1386-1389.
12. Kucher N, Walpoth N, Wustmann K, et al. QR in V1: An ECG sign associated with right ventricular strain and adverse clinical outcome in pulmonary embolism. Eur Heart J 2003; 24:1113-1119.
13. Jimenez D, Aujesky D, Diaz G, et al. Prognostic significance of deep vein thrombosis in patients presenting with acute symptomatic pulmonary embolism. Am J Respir Crit Care Med 2012; 181:983-991.
14. Pruszczyk P, Bochowicz A, Torbicki A, et al. Cardiac troponin T monitoring identifies high-risk group of normotensive patients with acute pulmonary embolism. Chest 2003; 123:1947-1952.
15. Kostrubiec M, Pruszczyk P, Bochowicz A, et al. Biomarker-based risk assessment model in acute pulmonary embolism. Eur Heart J 2005; 26: 2166-2172.
16. Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute pulmonary embolism: A meta-analysis. Circulation 2007; 116:427-433.
17. Jaff MR, McMurtry S, Archer SL, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: A scientific statement from the American Heart Association. Circulation 2011; 123:1788-1830.
18. Engelberger RP, Kucher N. Catheter-based reperfusion treatment of pulmonary embolism. Circulation 2011; 124:2139-2144.
19. Tapson VF. Fibrinolytic: (thrombolytic) therapy in acute pulmonary embolism and lower extremity deep vein thrombosis. Up To Date 2012. [Literature review current through August 2012; last updated 25 May 2012] Up To Date offers a very concise guide to thrombolytic therapy in acute pulmonary embolism that a clinician can quickly read through. 22. Kline JA, Hernandez-Nino J, Jones AE. Tenecteplase to treat pulmonary embolism in theemergency department. J Thromb Thrombolysis 2007; 23:101-105.
20. Kanter DS, Mikkola KM, Patel SR, et al. Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors. Chest 1997; 111:1241-1245.
21. Tapson VF, Gurbel PA, Stack RS. Pharmacomechanical thrombolysis of experimental pulmonary emboli: Rapid low-dose intraembolic therapy. Chest 1994; 106:1558-1562.
22. Greenfield LJ, Proctor MC, Williams DM, et al. Long-term experience with transvenous catheter pulmonary embolectomy. J Vasc Surg 1993; 18:450-457.
23. Schmitz-Rode T, Janssen U, Duda SH, et al. Massive pulmonary embolism: Percutaneous emergency treatment by pigtail rotation catheter. J Am Coll Cardiol 2000; 36:375-380.
24. Mü ller-Hü lsbeck S, Brossmann J, Jahnke T, et al. Mechanical thrombectomy of major and massive pulmonary embolism with use of the Amplatz thrombectomy device. Invest Radiol 2001; 36:317-322.
25. Fava M, Loyola S, Huete I. Massive pulmonary embolism: Treatment with the hydrolyser thrombectomy catheter. J Vasc Interv Radiol 2000; 11:1159-1164.
26. Reekers JA, Baarslag HJ, Koolen MG, et al. Mechanical thrombectomy for early treatment of massive pulmonary embolism. Cardiovasc Intervent Radiol 2003; 26:246-250.
27. Margheri M, Vittori G, Vecchio S, et al. Early and long-term clinical results of AngioJet rheolytic thrombectomy in patients with acute pulmonary embolism. Am J Cardiol 2008; 101:252-258.
28. Chamsuddin A, Nazzal L, Kang B, et al. Catheter-directed thrombolysis with the Endowave system in the treatment of acute massive pulmonary embolism: A retrospective multicenter case series. J Vasc Interv Radiol 2008; 19:372-376.
29. Mewissen MW, Seabrook GR, Meissner MH, et al. Catheter-directed thrombolysis for lower extremity deep venous thrombosis: Report of a national multicenter registry. Radiology 1999; 211:39-49.
30. Biederer J, Charalambous N, Paulsen F, et al. Treatment of acute pulmonary embolism: Local effects of three hydrodynamic thrombectomy devices in an ex vivo porcine model. J Endovasc Ther 2006; 13:549-560.
31. Danetz JS, McLafferty RB, Ayerdi J, et al. Pancreatitis caused by rheolytic thrombolysis: An unexpected complication. J Vasc Interv Radiol 2004; 15: 857-860.
32. PEITHO pulmonary embolism thrombolysis study. ClinicalTrials.gov NCT00639743. h tp://clinicaltrials.gov/ct2/show/NCT00639743